ATE190505T1 - Verwendung von ibuprofen-beta-cyclodextrin- komplex für die orale verabreichung - Google Patents

Verwendung von ibuprofen-beta-cyclodextrin- komplex für die orale verabreichung

Info

Publication number
ATE190505T1
ATE190505T1 AT93907987T AT93907987T ATE190505T1 AT E190505 T1 ATE190505 T1 AT E190505T1 AT 93907987 T AT93907987 T AT 93907987T AT 93907987 T AT93907987 T AT 93907987T AT E190505 T1 ATE190505 T1 AT E190505T1
Authority
AT
Austria
Prior art keywords
ibuprofen
beta
pct
cyclodextrin complex
oral administration
Prior art date
Application number
AT93907987T
Other languages
English (en)
Inventor
Timothy James Grattan
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE190505T1 publication Critical patent/ATE190505T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93907987T 1992-04-10 1993-04-02 Verwendung von ibuprofen-beta-cyclodextrin- komplex für die orale verabreichung ATE190505T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207990A GB9207990D0 (en) 1992-04-10 1992-04-10 Pharmaceutical composition
PCT/GB1993/000702 WO1993020850A1 (en) 1992-04-10 1993-04-02 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE190505T1 true ATE190505T1 (de) 2000-04-15

Family

ID=10713877

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93907987T ATE190505T1 (de) 1992-04-10 1993-04-02 Verwendung von ibuprofen-beta-cyclodextrin- komplex für die orale verabreichung

Country Status (12)

Country Link
US (1) US5597583A (de)
EP (1) EP0633787B1 (de)
JP (1) JPH07505645A (de)
KR (1) KR950700762A (de)
AT (1) ATE190505T1 (de)
AU (1) AU667095B2 (de)
CA (1) CA2117762A1 (de)
DE (1) DE69328087T2 (de)
ES (1) ES2145772T3 (de)
GB (1) GB9207990D0 (de)
NZ (1) NZ251393A (de)
WO (1) WO1993020850A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0760680A1 (de) * 1994-05-27 1997-03-12 Farmarc Nederland Bv Pharmazeutische zusammensetzungen
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
IT1301966B1 (it) 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
NZ524348A (en) * 2000-08-02 2004-07-30 Malope Company Ltd Diagnosis and treatment of non-ulcer dyspepsia based on dysfunction in the corticotropin releasing hormone (CRH) receptor and repsonse to ACTH
AU2002327418A1 (en) * 2001-08-01 2003-02-17 Bristol-Myers Squibb Company Taste masking composition
KR100567131B1 (ko) * 2004-01-05 2006-04-05 신일제약주식회사 쓴맛을 차폐한 아르기닌 함유 이부프로펜 경구투여 액상조성물
EP1942877A4 (de) * 2005-11-02 2011-09-14 Teikoku Pharma Usa Inc Organoleptisch annehmbare orale dosierformen von ibuprofen, herstellungsverfahren und anwendung
US20070207206A1 (en) * 2006-03-02 2007-09-06 Rice Bronwyn C Chewable pain formula
MX2008011823A (es) * 2006-03-16 2008-10-31 Novartis Ag Forma de dosificacion solida que contiene un agente activo de sabor encubierto.
DK2253329T3 (en) * 2009-04-27 2017-01-16 Laboratorio De Aplicaciones Farm S A Oral ibuprofen lysinate suspension.
US20120101159A1 (en) * 2009-04-27 2012-04-26 Laboratorio De Aplicaciones Farmacodinamicas, S.A. Ibuprofen lysinate oral suspension
CN114588107B (zh) * 2022-04-06 2023-04-18 河北一品生物医药有限公司 一种布洛芬赖氨酸盐注射液及其制备方法
EP4516290A1 (de) 2023-08-31 2025-03-05 Grindeks, A Joint Stock Company Pharmazeutische zusammensetzung aus einer kombination aus einem nichtsteroidalen antirheumatikum und einem dekongestivum in pulverform oder granulat zur herstellung eines heissgetränks

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
CA1298290C (en) * 1987-01-09 1992-03-31 Herand M. Markarian Solution ibuprofen complexes, compositions and processes for preparing the same
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
DE4038314A1 (de) * 1990-11-30 1992-06-04 Puetter Medice Chem Pharm Komplexe des aktiven enantiomers des ibuprofens mit cyclodextrin

Also Published As

Publication number Publication date
HK1012260A1 (en) 1999-07-30
WO1993020850A1 (en) 1993-10-28
DE69328087D1 (de) 2000-04-20
GB9207990D0 (en) 1992-05-27
KR950700762A (ko) 1995-02-20
EP0633787A1 (de) 1995-01-18
EP0633787B1 (de) 2000-03-15
JPH07505645A (ja) 1995-06-22
NZ251393A (en) 1996-08-27
US5597583A (en) 1997-01-28
AU3898793A (en) 1993-11-18
CA2117762A1 (en) 1993-10-28
ES2145772T3 (es) 2000-07-16
AU667095B2 (en) 1996-03-07
DE69328087T2 (de) 2000-08-24

Similar Documents

Publication Publication Date Title
DE69328087D1 (de) Verwendung von ibuprofen-beta-cyclodextrin-komplex für die orale verabreichung
DE69115280D1 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
DE69111077D1 (de) Chinazolinderivate um die antitumorwirkung zu verbessern.
AR038429A2 (es) Compuestos 15-alquil-16-hidroxilo de marcfortina
GB2270075B (en) Substituted 2-phenyl-3-methoxypropenoate fungicides
DE69109123D1 (de) Säures, flüssiges reinigungsmittel für badezimmer.
ES2132415T3 (es) Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol.
DK0699207T3 (da) Mellemprodukt til azithromycin
SE9502921D0 (sv) New compounds
DK0638075T3 (da) Thiazol- eller imidazolderivater som Maillard-reaktionsinhibitorer
ATE205868T1 (de) Monofilmmembran, verfahren zu ihrer herstellung und ihre verwendung
DE69225410D1 (de) Herstellung von n-acetylneuraminsäure-derivaten
ATE162683T1 (de) Pestizid und fungizid
MX9401406A (es) Agentes receptores de adenosina selectivos para intensificar el conocimiento.
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
DK0662967T3 (da) Syntese af N-acetyl-neuraminsyrederivater
ATE84074T1 (de) Verfahren zur fermentativen herstellung von 2-(4- hydroxiphenoxi-)propionsaeure.
DK0670837T3 (de)
NO941084D0 (no) Neuroleptiske 2-substituerte perhydro-1-H-pyrido[1,2-aÅpyraziner
TR26431A (tr) ANIYONIK AZO BOYAR MADDELERININ KONSANTRE, SULU CÖZELTILERININ üRETILMESINE MAHSUS USUL.
FI934977A0 (fi) Foerfarande foer att reducera elkfoerbrukningen i mikroprocessorbaserade,isynnerhet foer publika telefonstationer avsedda anordningar
DE59607683D1 (de) Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE69512087D1 (de) Monoazopigmente
ATE175971T1 (de) Wasserlösliche retinoide
GR3029357T3 (en) Method of preparing a radioactive rhenium complex solution.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties